Serum thyroglobulin determination in thyroid cancer patients

References 

1. Van Herle AJ, Uller RP, Matthews NL, et al. Radioimmunoassay for measurement of thyroglobulin in human serum. Journal of Clinical Investigation. 1973;52:1320–1327
2. Schlumberger MJ. Medical progress: papillary and follicular thyroid carcinoma. New England Journal of Medicine. 1998;338:297–306
3. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma : a European perspective. European Journal of Endocrinology. 2004;50:105–112
4. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:1–33
   • MEDLINE
   • CrossRef
5. Schlumberger M, Charbord P, Fragu P, et al. Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. Journal of Clinical Endocrinology and Metabolism. 1980;51:513–519
6. Lazar V, Bidart JM, Caillou B, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism. 1999;84:3228–3234
7. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism. 1999;84:3877–3885
8. Bachelot A, Cailleux AF, Klain M, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12:707–711
   • MEDLINE
   • CrossRef
9. Demers LM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyroid disease. [accessed 7-13-2002] http://www.nacb.org/lmpg/thyroid/LMPH.stm
10. Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism. 2003;88:1107–1111
11. Feldt-Rasmussen U, Profilis C, Colinet E, et al. Human thyroglobulin reference material (CRM 457). 2nd Part: physicochemical characterization and certification. Annales de Biologie Clinique (Paris). 1996;54:343–348
12. Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism. 2007;92:82–87
13. Iervasi A, Iervasi G, Ferdeghini M, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clinical Endocrinology (Oxford). 2007;67:434–441
14. Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism. 2007;92:2487–2495
15. Spencer CA. Challenges of serum thyroglobulin (thyroglobulin) measurement in the presence of thyroglobulin autoantibodies. Journal of Clinical Endocrinology and Metabolism. 2004;89:3702–3704
16. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 1998;83:1121–1127
17. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Annals of Internal Medicine. 2003;139:346–351
18. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low- risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2003;88:1433–1441
19. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. Journal of Nuclear Medicine. 2004;45:988–994
20. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clinical Endocrinology (Oxford). 2004;61:61–74
21. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. Journal of Clinical Endocrinology and Metabolism. 2000;85:175–178
22. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole–body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism. 2002;87:1499–1501
23. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2001;86:5686–5690
24. Kloos RT, Mazzaferri EL. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. Journal of Clinical Endocrinology and Metabolism. 2005;90:5047–5057
25. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant thyrotropin (rhTSH)-Stimulated Thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-Stimulated Thyroglobulin and undetectable basal serum thyroglobulin levels. Journal of Clinical Endocrinology and Metabolism. 2008;93:76–81
26. Pacini F, Molinaro E, Castagna MG, et al. rhTSH-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2003;88:3668–3673
27. Frasoldati A, Presenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97:90–96
    • MEDLINE
    • CrossRef
28. Torlontano M, Crocetti U, D'Aloiso L, et al. Serum thyroglobulin and ¹³¹I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. The role for neck ultrasonography. European Journal of Endocrinology. 2003;148:18–24
29. Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 1992;74:1401–1404
30. Frasoldati A, Toschi E, Zini M, et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. Thyroid. 1999;9:105–111
    • MEDLINE
    • CrossRef
31. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. European Journal of Endocrinology. 2006;154:787–803
32. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism. 2006;91:878–884
33. Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen^® and Thyroid hormone withdrawal. European Journal of Endocrinology. 2007;156:531–538
34. Luster M, Felbinger R, Dietlein M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma : a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmaco economic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147–1155
    • MEDLINE
    • CrossRef
35. Bachelot A, Leboulleux S, Baudin E, et al. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radio-iodine treatment. Clinical Endocrinology (Oxford). 2005;62:376–379
36. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?. Journal of Clinical Endocrinology and Metabolism. 2002;87:3242–3247
37. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. Journal of Clinical Endocrinology and Metabolism. 2004;89:3402–3407
38. Schlumberger M, Mancusi F, Baudin E, et al. ¹³¹I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273–276
    • MEDLINE
    • CrossRef
39. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic ¹³¹I whole body scan: comparison of patients treated with high ¹³¹I activities versus untreated patients. Journal of Clinical Endocrinology and Metabolism. 2001;86:4092–4097
40. Leboulleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology & Metabolism. 2007;3:112–121
    • MEDLINE
    • CrossRef
41. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of Fluoro-D-Glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2004;89:91–95
42. Travagli JP, Cailleux AF, Ricard M, et al. Combination of radio-iodine (¹³¹I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 1998;83:2675–2680
43. Durante C, Haddy N, Baudin E, et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radio-iodine therapy. Journal of Clinical Endocrinology and Metabolism. 2006;91:2892–2899